Molecular Basis and Potential Molecular Mechanisms of Action in Natural Products as Therapeutic Agents Towards Multiple Myeloma http://.www.doi.org/10.26538/tjnpr/v7i2.2
Article Sidebar
Main Article Content
Abstract
Multiple myeloma (MM) is a bone marrow-based neoplasm of clonal plasma cells resulting in substantial mortality and morbidity. It is classified as a mature B-cell neoplasm in which clonal plasma cell proliferation results in anaemia, hypercalcaemia and organ/tissue damage such as kidneys and skeletal system. The response rates of myeloma improved significantly following the introduction of novel therapies such as immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), monoclonal antibodies (MoAbs), hematopoietic stem cell transplant and cellular therapies such as chimeric antigen receptor (CAR) T-cells. However, MM remains incurable. In addition, adverse effects, exorbitant costs, and problems with accessibility to drugs and therapeutic modalities prevent many patients from reaping the potential benefits of these novel therapies. Therefore, it is essential to investigate new therapeutic targets and agents. Many cell signalling pathways are described in MM. Some facilitate the evasion of apoptosis and long periods of cell survival. Natural products contain a variety of secondary metabolites targeting these signalling pathways responsible for anti-MM activities such as apoptosis, cell cycle arrest, anti-angiogenesis, and miRNA modulation. The role of natural compounds as therapeutic agents in the treatment of multiple myeloma has drawn a considerable interest in research in recent past. This review attempts to collate available information on natural products from terrestrial plants, animals, and macrofungi, and their potential molecular mechanisms in MM.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
References
Ohana N, Rouvio O, Nalbandyan K, Sheinis D, Benharroch D. Classification of Solitary Plasmacytoma, Is it more Intricate than Presently Suggested? A Commentary. J Cancer. 2018; 9(21):3894–3897.
Huang J, Chan SC, Lok V, Zhang L, Lucero-Prisno DE, Xu W, Zheng ZJ, Elcarte E, Withers M, Wong MCS. The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. Lancet Haematol. 2022; 9(9):2230–2242.
Holstein SA, McCarthy PL. Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience. Drugs. 2017; 77(5):520–520.
Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, Prince HM. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010; 24(1):22–32.
Kang B, Park H, Kim B. Anticancer Activity and Underlying Mechanism of Phytochemicals against Multiple Myeloma. Int J Mol Sci. 2019; 20(9):1–24.
Jang HH. Regulation of Protein Degradation by Proteasomes in Cancer. J Cancer Prev. 2018; 23(4):153–161.
Bahlis NJ, Sutherland H, White D, Sebag M, Lentzsch S, Kotb R, Venner CP, Gasparetto C, Col A del, Neri P, Reece D, Kauffman M, Shacham S, Unger TJ, Jeha J, Saint-Martin JR, Shah J, Chen C. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma. Blood. 2018; 132(24):2546–2554.
Köhler M, Greil C, Hudecek M, Lonial S, Raje N, Wäsch R, Engelhardt M. Current developments in immunotherapy in the treatment of multiple myeloma. Cancer. 2018; 124(10):2075–2085.
Nishida H, Yamada T. Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets. J Oncol. 2019; 2019(special issue).
Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJT. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010; 9(4):325–338.
Baldo BA. Adverse events to monoclonal antibodies used for cancer therapy focus on hypersensitivity responses. Oncoimmunology. 2013; 2(10):e2633.
Sorokina M, Steinbeck C. Review on natural products databases: Where to find data in 2020. J Cheminform. 2020; 12(1):1–51.
Newman DJ, Cragg GM, Kingston DGI. Natural Products as Pharmaceuticals and Sources for Lead Structures. The Practice of Medicinal Chemistry: Fourth Edition. 2015; 101–139.
Yan Q, Lopes LD, Shaffer BT, Kidarsa TA, Vining O, Philmus B, Song C, Stockwell VO, Raaijmakers JM, McPhail KL, Andreote FD, Chang JH, Loper JE. Secondary metabolism and interspecific competition affect accumulation of spontaneous mutants in the GacS-GacA regulatory system in Pseudomonas protegens. mBio. 2018; 9(1):e01845–17.
Mazid M, Khan TA, Mohammad F. Role of secondary metabolites in defense mechanisms of plants. Biol Med. 2011; 3(2):232–249.
Vaishnav P, Demain AL. Unexpected applications of secondary metabolites. Biotechnol Adv. 2011; 29(2):223–229.
Stierle AA, Stierle DB. Bioactive secondary metabolites produced by the fungal endophytes of conifers. Nat Prod Commun. 2015; 10(10):1671–1682.
Seca AML, Pinto DCGA. Plant secondary metabolites as anticancer agents: Successes in clinical trials and therapeutic application. Int J Mol Sci. 2018; 19(1):263 –285.
Cardozo KHM, Guaratini T, Barros MP, Falcão VR, Tonon AP, Lopes NP, Campos S, Torres MA, Souza AO, Colepicolo P, Pinto E. Metabolites from algae with economical impact. Comp Biochem Physiol C Toxicol Pharmacol. 2007; 146(1-2):60–78.
Wink M. Medicinal plants: A source of anti-parasitic secondary metabolites. Molecules. 2012; 17(11):12771–12791.
Yadav AN, Kumar R, Kumar S, Kumar V, Sugitha TCK, Singh B, Chauahan VS, Dhaliwal HS, Saxena AK. Beneficial microbiomes: Biodiversity and potential biotechnological applications for sustainable agriculture and human health. J Appl Biol Biotechnol. 2017; 5(6):45–57.
Beutler JA. Natural Products as a Foundation for Drug Discovery. Curr Protoc Pharmacol. 2019; 86(1):67–107.
Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod. 2012; 75(3):311–35.
Newman DJ, Cragg GM. Natural Products as Sources of New Drugs from 1981 to 2014. J Nat Prod. 2016; 79(3):629–661.
Kinghorn AD, Chin YW, Swanson SM. Discovery of natural product anticancer agents from biodiverse organisms. Curr Opin Drug Discov Devel. 2009; 12(2):189–196.
DeVita VT, Chu E. A history of cancer chemotherapy. Cancer Res. 2008; 68(21):8643–8653.
Jimenez PC, Wilke DV, Costa-Lotufo LV. Marine drugs for cancer: Surfacing biotechnological innovations from the oceans. Clinics. 2018; 73:e482s.
Cragg GM, Pezzuto JM. Natural Products as a Vital Source for the Discovery of Cancer Chemotherapeutic and Chemopreventive Agents. Med Princ Pract. 2016; 25(2):41–59.
Coimbra M, Isacchi B, Van Bloois L, Torano JS, Ket A, Wu X, Broere F, Metselaar JM, Rijcken CJF, Storm G, Bilia R, Schiffelers RM. Improving solubility and chemical stability of natural compounds for medicinal use by incorporation into liposomes. Int J Pharm. 2011; 416(2):433–442.
Pojero F, Poma P, Spanò V, Montalbano A, Barraja P, Notarbartolo M. Targeting multiple myeloma with natural polyphenols. Eur J Med Chem. 2019; 180:465–485.
Yang LJ, Chen Y, He J, Yi S, Wen L, Zhao S, Cui GH. Effects of gambogic acid on the activation of caspase-3 and downregulation of SIRT1 in RPMI-8226 multiple myeloma cells via the accumulation of ROS. Oncol Lett. 2012; 3(5):1159–1165.
Young K, Jeong S jin, Kim S hee, Hoon J, Kim J hyun, Koh W, Chen C yan, Kim S hoon. Activation of reactive oxygen species / AMP activated protein kinase signaling mediates fisetin-induced apoptosis in multiple myeloma U266 cells. Cancer Lett. 2012; 319(2):197–202.
Prasad S, Pandey MK, Yadav VR, Aggarwal BB. Gambogic acid inhibits STAT3 phosphorylation through activation of protein tyrosine phosphatase SHP-1: Potential role in proliferation and apoptosis. Cancer Prev Res (Phila). 2011; 4(7):1084–1094.
Pandey MK, Kale VP, Song C, Sung S shu, Sharma AK, Talamo G, Dovat S, Amin SG. Gambogic acid inhibits multiple myeloma mediated osteoclastogenesis through suppression of chemokine receptor CXCR4 signaling pathways. Exp Hematol. 2014; 42(10):883–896.
Wang F, Zhang W, Guo L, Bao W, Jin N, Liu R, Liu P, Wang Y, Guo Q, Chen B. Gambogic acid suppresses hypoxia-induced hypoxia-inducible factor-1α/vascular endothelial growth factor expression via inhibiting phosphatidylinositol 3-kinase/Akt/mammalian target protein of rapamycin pathway in multiple myeloma cells. Cancer Sci. 2014; 105(8):1063–1070.
Fu R, Chen Y, Wang XP, An T, Tao L, Zhou YX, Huang YJ, Chen BA, Li ZY, You QD, Guo QL, Wu ZQ. Wogonin inhibits multiple myeloma-stimulated angiogenesis via cMyc/VHL/HIF-1a signaling axis. Oncotarget. 2016; 7(5):5715–5727.
Boissy P, Andersen TL, Abdallah BM, Kassem M, Plesner T, Delaissé JM. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation. Cancer Res. 2005; 65(21):9943–9952.
Chong PSY, Chng WJ, de Mel S. STAT3: A promising therapeutic target in multiple myeloma. Cancers (Basel). 2019; 11(5):1–15.
Sun C, Hu Y, Liu X, Wu T, Wang Y, He W, Wei W. Resveratrol downregulates the constitutional activation of nuclear factor-κB in multiple myeloma cells, leading to suppression of proliferation and invasion, arrest of cell cycle, and induction of apoptosis. Cancer Genet Cytogenet.
; 165(1):9–19.
Bharti AC, Donato N, Singh S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-κB and IκBα kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood. 2003; 101(3):1053–1062.
Lin CC, Ng LT, Hsu FF, Shieh DE, Chiang LC. Cytotoxic effects of Coptis chinensis and Epimedium sagittatum extracts and their major constituents (berberine, coptisine and icariin) on hepatoma and leukaemia cell growth. Clin Exp Pharmacol Physiol. 2004; 31(1-2):65–69.
Jung YY, Lee JH, Nam D, Narula AS, Namjoshi OA, Blough BE, Um JY, Sethi G, Ahn KS. Antimyeloma effects of icariin are mediated through the attenuation of JAK/STAT3-dependent signaling cascade. Front Pharmacol. 2018; 9:1–15.
Zhu S, Wang Z, Li Z, Peng H, Luo Y, Deng M, Li R, Dai C, Xu Y, Liu S, Zhang G. Icaritin suppresses multiple myeloma, by inhibiting IL-6/JAK2/STAT3. Oncotarget. 2015; 6(12):10460–10472.
Yamasaki H. Pharmacology of sinomenine, an anti rheumatic alkaloid from Sinomenium acutum. Acta Med Okayama. 1976; 30(1):1–20.
Wang Y, Wu L, Cai H, Lei H, Ma CM, Yang L, Xu H, Zhu Q, Yao Z, Wu Y. YL064 directly inhibits STAT3 activity to induce apoptosis of multiple myeloma cells. Cell Death Discov. 2018; 4(1):1–10.
Marin EH, Paek H, Li M, Ban Y, Karaga MK, Shashidharamurthy R, Wang X. Caffeic acid phenethyl ester exerts apoptotic and oxidative stress on human multiple myeloma cells. Invest New Drugs. 2019; 37(5):837–848.
Ma Z, Otsuyama KI, Liu S, Abroun S, Ishikawa H, Tsuyama N, Obata M, Li FJ, Zheng X, Maki Y, Miyamoto K, Kawano MM. Baicalein, a component of Scutellaria radix from Huang-Lian-Jie-Du-Tang (HLJDT), leads to suppression of proliferation and induction of apoptosis in
human myeloma cells. Blood. 2005; 105(8):3312–3318.
Liu XP, He L, Zhang QP, Zeng XT, Liu SQ. Baicalein inhibits proliferation of myeloma U266 cells by downregulating IKZF1 and IKZF3. Med Sci Monit. 2018; 24:2809–2817.
He H, Chen L, Zhai M, Chen JZS. Genistein Downregulates The Constitutive Activation of Nuclear Factor-κB in Human Multiple Myeloma Cells, Leading to Suppression of Proliferation and Induction of Apoptosis. Phytother Res. 2009; 23:868–873.
Yang Y, Zhou X, Xiao M, Hong Z, Gong Q, Jiang L, Zhou J. Discovery of chrysoeriol, a PI3K-AKT-mTOR pathway inhibitor with potent antitumor activity against human multiple myeloma cells in vitro. J Huazhong Univ Sci Technolog Med Sci. 2010; 30(6):734–740.
Zhang M, Liu LP, Chen Y, Tian XY, Qin J, Wang D, Li Z, Mo SL. Wogonin induces apoptosis in RPMI 8226, a human myeloma cell line, by downregulating phospho-Akt and overexpressing Bax. Life Sci. 2013; 92(1):55–62.
Lin MG, Liu LP, Li CY, Zhang M, Chen Y, Qin J, Gu YY, Li Z, Wu XL, Mo SL. Scutellaria extract decreases the proportion of side population cells in a myeloma cell line by down-regulating the expression of ABCG2 protein. Asian Pac J Cancer Prev. 2013; 14(12):7179–7186.
Gu YY, Liu LP, Qin J, Zhang M, Chen Y, Wang D, Li Z, Tang JZ, Mo SL. Baicalein decreases side population proportion via inhibition of ABCG2 in multiple myeloma cell line RPMI 8226 in vitro. Fitoterapia. 2014; 94:21–28.
Shanbhag VKL. Applications of snake venoms in treatment of cancer. Asian Pac J Trop Biomed. 2015; 5(4):275–276.
Utkin YN. Animal venom studies: Current benefits and future developments. World J Biol Chem. 2015; 6(2):28–33.
Chen N, Xu S, Zhang Y, Wang F. Animal protein toxins: origins and therapeutic applications. Biophys Rep. 2018; 4(5):233–242.
Duffy C, Sorolla A, Wang E, Golden E, Woodward E, Davern K, Ho D, Johnstone E, Pfleger K, Redfern A, Iyer KS, Baer B, Blancafort P. Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer. npj Precis Onc.
; 4(1):1–16.
Kim C, Kim DS, Nam D. Melittin exerts antitumorigenic effects in human MM1.S multiple myeloma cells through the suppression of AKT / mTOR / S6K1 / 4E-BP1 signaling cascades. Orient Pharm. Exp. Med. 2015; 15(1),33–44.
Al-sadoon MK, Rabah DM, Badr G. Enhanced anticancer efficacy of snake venom combined with silica nanoparticles in a murine model of human multiple myeloma: molecular targets for cell cycle arrest and apoptosis induction. Cell Immunol. 2013; 284(1-2):129–138.
Ayeka PA. Potential of Mushroom Compounds as Immunomodulators in Cancer Immunotherapy: A Review. Evid Based Complement Alternat Med. 2018; 2018.
Fernando DM, Wijesundera RLC, Soysa P, de Silva D, Nanayakkara CM. Antioxidant potential, in vitro cytotoxicity and apoptotic effect induced by crude organic extract of Anthracophyllum lateritium against RD sarcoma cells. BMC Complement Altern Med. 2015; 15(1):1–9.
Isham CR, Tibodeau JD, Jin W, Xu R, Timm MM, Bible KC. Chaetocin: A promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress. Blood. 2007; 109(6):2579–88.
Müller CI, Kumagai T, O’Kelly J, Seeram NP, Heber D, Koeffler HP. Ganoderma lucidum causes apoptosis in leukemia, lymphoma and multiple myeloma cells. Leuk Res. 2006; 30(7):841–848.
Murakawa K, Fukunaga K, Tanouchi M, Hosokawa M, Hossain Z, Takahashi K. Therapy of myeloma in vivo using marine phospholipid in combination with Agaricus blazeiMurill as an immune respond activator. J Oleo Sci. 2007; 56(4):179–188.
Tangen JM, Holien T, Mirlashari MR, Misund K, Hetland G. Cytotoxic effect on human myeloma cells and leukemic cells by the Agaricus blazei Murill based mushroom extract, andosanTM. Biomed Res Int. 2017; 2017:1–7.
Tangen JM, Tierens A, Caers J, Binsfeld M, Olstad OK, Trøseid AMS, Wang J, Tjonnfjord GR, Hetland Geir. Immunomodulatory effects of the Agaricus blazei Murrillbased mushroom extract andosan in patients with multiple myeloma undergoing high dose chemotherapy and autologous stem cell transplantation: A randomized, double blinded clinical study. Biomed Res Int. 2015; 2015:718539.
Hetland G, Johnson E, Lyberg T, Bernardshaw S, Tryggestad AMA, Grinde B. Effects of the medicinal mushroom Agaricus blazei Murill on immunity, infection and cancer. Scand J Immunol. 2008; 68(4):363–370.
Chan GCF, Chan WK, Sze DMY. The effects of betaglucan on human immune and cancer cells. J Hematol Oncol. 2009; 2:25.
Yan X, Qi M, Li P, Zhan Y, Shao H. Apigenin in cancer therapy: anticancer effects and mechanisms of action. Cell Biosci. 2017; 7(50):50 –66.
Liu H, Dong Y, Gao Y, Du Z, Wang Y, Cheng P, Chen A, Huang H. The Fascinating Effects of Baicalein on Cancer: A Review. Int J Mol Sci. 2016; 17(10):1–18.
Murugesan A, Lassalle-Claux G, Hogan L, Vaillancourt E, Selka A, Luiker K, Kim MJ, Touaibia M, Reiman T. Antimyeloma Potential of Caffeic Acid Phenethyl Ester and Its Analogues through Sp1 Mediated Downregulation of IKZF1-IRF4-MYC Axis. J Nat Prod. 2020; 83(12):3526–3535.
Qin Y, Sun CY, Lu FR, Shu XR, Yang D, Chen L, She XM, Gregg NM, Guo T, Hu Y. Cardamonin exerts potent activity against multiple myeloma through blockade of NF-κB pathway in vitro. Leuk Res. 2012; 36(4):514–520.
Ramchandani S, Naz I, Dhudha N, Garg M. An overview of the potential anticancer properties of cardamonin. Explor Target Antitumor Ther. 2020; 1(6):413–426.
Bai QX, Zhang XY. Curcumin Enhances Cytotoxic Effects of Bortezomib in Human Multiple Myeloma H929 Cells: Potential Roles of NF-κB/JNK. Int J Mol Sci. 2012; 13(4):4831–4838.
Allegra A, Speciale A, Molonia MS, Guglielmo L, Musolino C, Ferlazzo G, Costa G, Saija A, Cimino F. Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-κB pathways. Toxicol In Vitro. 2018; 47:186–194.
Kang KA, Piao MJ, Madduma Hewage SRK, Ryu YS, Oh MC, Kwon TK, Chae S, Hyun JW. Fisetin induces apoptosis and endoplasmic reticulum stress in human nonsmall cell lung cancer through inhibition of the MAPK signaling pathway. Tumour Biol. 2016; 37(7):9615–9624.
Kashyap D, Garg VK, Tuli HS, Yerer MB, Sak K, Sharma AK, Kumar M, Aggarwal V, Sandhu SS. Fisetin and Quercetin: Promising Flavonoids with Chemopreventive Potential. Biomolecules. 2019; 9(5):174 –195.
Yu CC, Li Y, Cheng ZJ, Wang X, Mao W, Zhang YW. Active Components of Traditional Chinese Medicinal Material for Multiple Myeloma: Current Evidence and Future Directions. Front Pharmacol. 2022; 13:1–11.
Xie J, Wang J, Zhu B. Genistein inhibits the proliferation of human multiple myeloma cells through suppression of nuclear factor-κB and upregulation of microRNA-29b. Mol Med Rep. 2016; 13(2):1627–1632.
Tan HL, Chan KG, Pusparajah P, Saokaew S, Duangjai A, Lee LH, Goh BH. Anticancer Properties of the Naturally Occurring Aphrodisiacs: Icariin and Its Derivatives. Front Pharmacol. 2016; 7:1–18.
He D, Guo X, Zhang E, Zi F, Chen J, Chen Q, Lin X, Yang L, Li Y, Wu W, Yang Y, He J, Cai Z. Quercetin induces cell apoptosis of myeloma and displays a synergistic effect with dexamethasone in vitro and in vivo xenograft models. Oncotarget. 2016; 7(29):45489–45499.
Li Q, Yue Y, Chen L, Xu C, Wang Y, Du L, Xue X, Liu Q, Wang Y, Fan F. Resveratrol sensitizes carfilzomib-induced apoptosis via promoting oxidative stress in multiple myeloma cells. Front Pharmacol. 2018; 9:1–11.
Wang Y, Wu L, Cai H, Lei H, Ma CM, Yang L, Xu H, Zhu Q, Yao Z, Wu Y. Sinomenine derivative YL064: a novel STAT3 inhibitor with promising antimyeloma activity. Cell Death Dis. 2018; 9(11):1–3.
Sharifi-Rad J, Herrera-Bravo J, Salazar LA, Shaheen S, Abdulmajid Ayatollahi S, Kobarfard F, Imran M, Imran A, Custódio L, Dolores López M, Schoebitz M, Martorell M, Kumar M, Ansar Rasul Suleria H, Cho WC. The Therapeutic Potential of Wogonin Observed in Preclinical Studies. Evid Based Complement Alternat Med. 2021; 2021:9935451.
Jung HJ, Seo I, Casciello F, Jacquelin S, Lane SW, Suh S il, Suh MH, Lee JS, Baek WK. The anticancer effect of chaetocin is enhanced by inhibition of autophagy. Cell Death & Dis . 2016; 7(2):e2098.
Jiang H, Li Y, Xiang X, Tang Z, Liu K, Su O, Zhang X, Li L. Chaetocin: A review of its anticancer potentials and mechanisms. Eur J Pharmacol. 2021; 910:1–10.